Improved glycemic control and lifestyle behaviors with Dexcom continuous glucose monitoring: one-year real-world outcomes from a global registry of people with non-insulin-treated type 2 diabetes in primary care
Year: 2026
Type: article
Abstract: Aims Real-world evidence for continuous glucose monitoring (CGM) in non-insulin-treated (NIT) type 2 diabetes (T2D) remains limited. We evaluated one-year Dexcom G7 CGM use in adults with NIT T2D in US primary care. Methods In this non-randomized registry study (NCT06483945), adults with NIT T2D from 10 US primary care sites initiated Dexcom G7 CGM while continuing usual care. Outcomes included 12-month HbA1c change, (primary), CGM use, weight, BMI, and psychosocial and behavioral measures. Results Participants (N = 318) were 54% male, 40% non-white, mean age 61 years, and mean BMI 31 kg/m 2 ; 39% had low income. Mean HbA1c decreased by −0.66% at 12 months (95% CI: −0.83% to −0.49%, p < 0.001; n = 171), with similar reductions across age and medication subgroups. Most participants (73.5%) used CGM ≥70% of the time. CGM use was also associated with reduced body weight and BMI (weight, −2.4 kg [95% CI: −3.2, −1.6]; BMI, −0.8 kg/m 2 [95% CI: −1.1, −0.5]) and improved diabetes-related distress (2.2 [0.9] to 1.8 [0.8], p < 0.001), dietary patterns, and lifestyle behaviors. Conclusions In real-world primary care, Dexcom G7 CGM use in NIT T2D was associated with improved glycemia, weight, diabetes distress, diet, and lifestyle behaviors, supporting CGM adoption beyond insulin-treated populations.
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,410
OpenAlex ID: W7225815575